Lower Risk of Infectious Deaths in Cardiac Transplant Patients Receiving Basiliximab Versus Anti-thymocyte Globulin as Induction Therapy

Is Lymphocytic Bronchiolitis a Marker of Acute Rejection? An Analysis of 2,697 Transbronchial Biopsies After Lung Transplantation

“…For example, increased LB resulting from infection due to over-immunosuppression in the group receiving polyclonal induction may be offset by a reduction in LB attributable to acute rejection. 17,22 Similarly, although LB attributable to an alloimmune pathogenesis may not be expected to be very different between transplant procedures, the risk of LB attributable to infectious processes could be much higher in patients receiving SLT owing to the presence of the native lung and the subsequent increased risk of contamination of the lung allograft by sequestered microorganisms.…”

Infectious Complications Associated with Monoclonal Antibodies and Related Small Molecules

“…Among liver transplant patients, basiliximab-treated patients actually had a lower incidence of HCV recurrence and no difference in posttransplantation lymphoproliferative disease or CMV incidence (137). In cardiac transplant patients, basiliximab treatment had a lower incidence of infectious deaths than did ATG treatment (110).…”

Induction Therapy With Thymoglobulin After Heart Transplantation: Impact of Therapy Duration on Lymphocyte Depletion and Recovery, Rejection, and Cytomegalovirus Infection Rates

“…[3][4][5] The disadvantage of using these powerful immunosuppressants is the possibility of increased adverse events, including the incidence of infections in the early phase 6 and malignancies in the long-term. 7,8 No published reports, to our knowledge, have compared different regimens of polyclonal anti-thymocyte globulin (ATG) on cellular rejection.…”